Special Issue "Cancer Immunotherapies"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2016) | Viewed by 64754
2. Department of Medicine, University of Oklahoma, Oklahoma City, OK 73126, USA
Interests: Immunotherapy; CAR-T cells; tumor microenvironment; checkpoint protein; hypoxia; tumor survival signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Cancer Stem Cells and Tumor Microenvironment
Special Issue in Cancers: CAR-T Cell Therapy against Different Types of Cancer
Special Issue in Cancers: CAR-T Cell Therapy-Novel Approaches and Challenges
Special Issue in Cancers: Immunotherapy, Tumor Microenvironment and Survival Signaling
Special Issue in Vaccines: Advances in Vaccine Development and Immunotherapies
Special Issue in Cancers: Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer
Cancer immunotherapy (therapy that uses a person's immune system to fight cancer) has become an important field of oncology. There are four main types of immunotherapies: monoclonal antibodies; cancer vaccines; checkpoint inhibitors; and non-specific cancer immunotherapies (therapies that do not target cancer specifically, but stimulate immune cells that can lead to anti-cancer immune response, such as interleukins, cytokines, interferons, and others). Tumors express ligands to immune checkpoint proteins, such as PD-1 (programmed cell death 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), mediating block of immune response. Thus, the development of inhibitors of these immune checkpoint pathways is a promising area of immune therapeutics. In addition, tumors express tumor antigens that can be targeted with antibodies; antibody-drug conjugates; chimeric antigen receptor (CAR) T cells; or by other approaches. Dendritic cell vaccine is another important immunotherapy approach against cancer. This Special Issue is focused on recent immunotherapy approaches, novel immune therapeutics, and immunology signaling pathways in cancer.
Dr. Vita Golubovskaya
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- CAR-T cell
- dendritic cell
- tumor antigen
- monoclonal antibody